Cryopreservation of T regulatory cells

Stanford researchers have developed a method to activate, cryopreserve, and thaw T regulatory (Tregs) cells that preserves their viability, phenotype and function. As compared to current standard techniques for cryopreservation, this new method minimizes manipulation and improves cell viability to retain therapeutic effect.
Tregs are useful in a variety of conditions, including but not limited to the treatment of cancer, in association with hematopoietic stem cell transplantation (HCT). Additionally, Tregs can help reduce graft vs host disease (GVHD) and allograft rejection.
For example, a population of cells comprising cryopreserved Tregs can be administered to an HCT recipient subject, and the population of Tregs can serve to reduce or prevent GVHD in the HCT recipient subject.

Stage of Development
Clinical testing